SPOTLIGHT: Par to restate earnings

Generic drug maker Par Pharmaceutical announced that it will restate financial results for 2004 and 2005 and the first quarter of 2006 which will reduce earnings for that period by $55 million. The adjustment is the result of an understatement of accounts receivable reserves. Par now faces class-action suits for violating sections of the Securities Exchange Act of 1934. Report [1]